GHRP-6

ID: ghrp6

Aliases: GHRP-6 ACETATE, growth hormone releasing hexapeptide-6

Type: compound

Route/form: injection in older human physiology contexts; formulation varies by study

Status: research

Evidence level: early human

Best data tier: human physiology

Support scope: human, review/regulatory

Source types: human_physiology, review

Linked sources: 2

Broad outcomes: Fat loss / metabolic health, Hormones / fertility / sexual health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• ghrelin receptor / GHSR agonism
• growth hormone release
• appetite stimulation

Optimization domains

• growth hormone
• endocrine
• appetite
• muscle

Research basis

• GHRP-6 is included because older human diagnostic/physiology work shows GH-response activity and it is a common reference point for GHRP-class discussions.
• Mechanistically it belongs with GHRP-2, hexarelin, and ipamorelin as a growth-hormone secretagogue rather than a direct anabolic drug.
• It helps explain why appetite, ghrelin signaling, and GH pulses get bundled in community protocols.

Limits, risks, and missing evidence

• The human evidence is not a modern performance or body-composition outcome package.
• Appetite, glucose, edema, cortisol/prolactin, and endocrine-feedback concerns can dominate practical use.
• Data quality and clinical relevance are weaker than the frequency of community claims would suggest.

Risk flags

• investigational
• endocrine axis
• ghrelin receptor
• limited outcome data

Linked papers, labels, and reviews

1. Growth hormone releasing hexapeptide-6 test in the diagnosis of GH-deficiency
   human_physiology / pubmed_ghrp6_gh_deficiency_test_1996
   Older human diagnostic physiology source for GHRP-6.
2. Growth hormone-releasing peptides
   review / pubmed_ghrp_review_1997
   Class review for GHRP-2, GHRP-6, hexarelin, and related secretagogues.